Live Breaking News & Updates on Verrica Pharmaceuticals Stock

Stay updated with breaking news from Verrica pharmaceuticals stock. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Verrica Pharmaceuticals (NASDAQ:VRCA) Price Target Increased to $12.00 by Analysts at HC Wainwright

Verrica Pharmaceuticals (NASDAQ:VRCA – Free Report) had its price objective hoisted by HC Wainwright from $11.00 to $12.00 in a report issued on Thursday morning, Marketbeat.com reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Verrica Pharmaceuticals’ FY2026 earnings at $0.45 EPS. Several other equities research analysts […] ....

Blackrock , Nova-scotia , Canada , United-states , Paulb-manning , Ted-white , Securities-exchange-commission , Institutional-investors-weigh-in-on-verrica-pharmaceuticals , Blackrock-inc , Verrica-pharmaceuticals , Avoro-capital-advisors , Capital-management

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) CEO Ted White Sells 50,677 Shares of Stock

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA – Get Free Report) CEO Ted White sold 50,677 shares of the business’s stock in a transaction that occurred on Monday, July 24th. The stock was sold at an average price of $4.83, for a total transaction of $244,769.91. Following the completion of the sale, the chief executive officer now owns […] ....

United-states , Canada , Ted-white , News-ratings-for-verrica-pharmaceuticals-daily , Verrica-pharmaceuticals-company-profile , Needham-company , Nasdaq , Royal-bank , Cubist-systematic-strategies , Virtu-financial , Verrica-pharmaceuticals , Tower-research-capital

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Insider Christopher G. Hayes Sells 33,789 Shares of Stock

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA – Get Free Report) insider Christopher G. Hayes sold 33,789 shares of the stock in a transaction on Monday, July 24th. The stock was sold at an average price of $4.83, for a total transaction of $163,200.87. Following the transaction, the insider now directly owns 81,925 shares in the company, valued […] ....

United-states , Canada , Christopherg-hayes , Verrica-pharmaceuticals-stock , Verrica-pharmaceuticals-inc , Verrica-pharmaceuticals , Manchester-capital-management , Tower-research-capital , Goldman-sachs-group-inc , Citigroup-inc , Securities-exchange-commission

Jefferies Financial Group Begins Coverage on Verrica Pharmaceuticals (NASDAQ:VRCA)

Jefferies Financial Group started coverage on shares of Verrica Pharmaceuticals (NASDAQ:VRCA – Get Rating) in a research report sent to investors on Wednesday morning, The Fly reports. The firm issued a buy rating and a $10.00 price objective on the stock. Jefferies Financial Group also issued estimates for Verrica Pharmaceuticals’ Q1 2023 earnings at ($0.20) […] ....

Canada , Blackrock , Nova-scotia , News-ratings-for-verrica-pharmaceuticals-daily , Jefferies-financial-group , Royal-bank , Verrica-pharmaceuticals-stock , Verrica-pharmaceuticals-company-profile , Verrica-pharmaceuticals , Capital-management , Blackrock-inc